Miquel Navasa

Miquel Navasa

Auto-generated profile, based on publicly available information

Miquel Navasa

Liver Unit, Hospital Clínic, IDIBAPS and CIBEREHD, University of Barcelona

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2006 in Gastroenterology
Verified
Journal Article
Open access
PDF file
JFJavier Fernández
Javier Fernández
LALuis Ruiz del Arbol
Luis Ruiz del Arbol
CGCristina Gómez
Cristina Gómez
RDRosa Durandez
Rosa Durandez
RSRegina Serradilla
Regina Serradilla
MNMiguel Navasa
Miguel Navasa
Background & Aims: Oral norfloxacin is the standard of therapy in the prophylaxis of bacterial infections in cirrhotic patients with gastrointestinal hemorrhage. However, during the last years, the epidemiology of bacterial infections in cirrhosis has changed, with a higher incidence of infections caused by quinolone-resistant bacteria. This randomized controlled trial was aimed to compare oral norfloxacin vs intravenous ceftriaxone in the prophylaxis of bacterial infection in cirrhotic patients with gastrointestinal bleeding. Methods: One hundred eleven patients with advanced cirrhosis (at least 2 of the following: ascites, severe malnutrition, encephalopathy, or bilirubin >3 mg/dL) and gastrointestinal hemorrhage were randomly treated with oral norfloxacin (400 mg twice daily; n = 57) or intravenous ceftriaxone (1 g/day; n = 54) for 7 days. The end point of the trial was the prevention of bacterial infections within 10 days after inclusion. Results: Clinical data were comparable between groups. The probability of developing proved or possible infections, proved infections, and spontaneous bacteremia or spontaneous bacterial peritonitis was significantly higher in patients receiving norfloxacin (33% vs 11%, P = .003; 26% vs 11%, P = .03; and 12% vs 2%, P = .03, respectively). The type of antibiotic used (norfloxacin), transfusion requirements at inclusion, and failure to control bleeding were independent predictors of infection. Seven gram-negative bacilli were isolated in the norfloxacin group, and 6 were quinolone resistant. Nonenterococcal streptococci were only isolated in the norfloxacin group. No difference in hospital mortality was observed between groups. Conclusions: Intravenous ceftriaxone is more effective than oral norfloxacin in the prophylaxis of bacterial infections in patients with advanced cirrhosis and hemorrhage.

23 December 2009 in Hepatology
Verified
Journal Article
Open access
PDF file
JCJosé A. Carrión
José A. Carrión
FTFerran Torres
Ferran Torres
GCGonzalo Crespo
Gonzalo Crespo
RMRosa Miquel
Rosa Miquel
JGJuan-Carlos García-Valdecasas
Juan-Carlos García-Valdecasas
XFXavier Forns
Xavier Forns
Significant liver fibrosis (F ≥ 2) and portal hypertension (hepatic venous pressure gradient [HVPG] ≥ 6 mmHg) at 1 year after liver transplantation (LT) identify patients with severe hepatitis C recurrence. We evaluated whether repeated liver stiffness measurements (LSM) following LT can discriminate between slow and rapid “fibrosers” (fibrosis stage F2-F4 at 1 year after LT). Eighty-four patients who had undergone LT and who were infected with hepatitis C virus (HCV) and 19 LT controls who were not infected with HCV underwent LSM at 3, 6, 9, and 12 months after LT. All HCV-infected patients underwent liver biopsy 12 months after LT (paired HVPG measurements in 74); 31 (37%) were rapid fibrosers. Median LSM (in kilopascal) at months 6, 9, and 12 were significantly higher in rapid fibrosers (9.9, 9.5, 12.1) than in slow fibrosers (6.9, 7.5, 6.6) ( P < 0.01 all time points). The slope of liver stiffness progression (kPa × month) in rapid fibrosers (0.42) was significantly greater than in slow fibrosers (0.05) ( P < 0.001), suggesting two different speeds of liver fibrosis progression. Figures were almost identical for patients with HVPG ≥ 6 mmHg or HVPG < 6 mmHg at 1 year after LT. Multivariate analysis identified donor age, bilirubin level, and LSM as independent predictors of fibrosis progression and portal hypertension in the estimation group (n = 50) and were validated in a second group of 34 patients. The areas under the receiver operating characteristic curve that could identify rapid fibrosers and patients with portal hypertension as early as 6 months after LT were 0.83 and 0.87, respectively, in the estimation group and 0.75 and 0.80, respectively, in the validation group. Conclusion: Early and repeated LSM following hepatitis C recurrence in combination with clinical variables discriminates between rapid and slow fibrosers after LT. (Hepatology 2009.)

1 January 2010 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
JCJosé A. Carrión
José A. Carrión
GFGuillermo Fernández-Varo
Guillermo Fernández-Varo
MBMiquel Bruguera
Miquel Bruguera
JGJuan Carlos García-Pagán
Juan Carlos García-Pagán
JGJuan–Carlos García–Valdecasas
Juan–Carlos García–Valdecasas
MNMiquel Navasa
Miquel Navasa

1 October 2014 in Clinical Immunology
Verified
Journal Article
Closed access
OMO. Millán
O. Millán
LRL. Rafael-Valdivia
L. Rafael-Valdivia
DSDavid San Segundo
David San Segundo
FBFrancisco Boix
Francisco Boix
MCM.J. Castro-Panete
M.J. Castro-Panete
MBMercè Brunet
Mercè Brunet

18 August 2021 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
EFEsther Fernández-Galán
Esther Fernández-Galán
CBCelia Badenas
Celia Badenas
CFConstantino Fondevila
Constantino Fondevila
WJWladimiro Jiménez
Wladimiro Jiménez
MNMiquel Navasa
Miquel Navasa
MBMercè Brunet
Mercè Brunet
Monitoring of graft function is essential during the first months after liver transplantation (LT), but current liver function tests (LFTs) lack the specificity and sensitivity to ensure an efficient diagnosis of acute rejection (AR). Recently, donor‐derived cell‐free DNA (ddcfDNA) has emerged as a noninvasive biomarker to assess graft integrity. This study evaluated the feasibility of measuring the ddcfDNA through short tandem repeat (STR) analysis by quantitative fluorescent‐polymerase chain reaction (QF‐PCR) and to assess the role of the concentration and fragment size of total cfDNA as AR biomarkers. The total concentration and fragment size of cfDNA and the ddcfDNA percentage were monitored in plasma of 20 patients without rejection and 7 patients with T‐cell–mediated AR during the first 3 months after LT. The median ddcfDNA percentage was 3‐fold higher before AR diagnosis (34.8%; P < 0.001) and moderately higher at AR confirmatory diagnosis (23.8%; P = 0.049) compared with that of nonrejector patients (10.6%), showing a better performance (area under the curve = 84.6%) than conventional LFTs to predict the risk of rejection within the first 2 weeks following LT. The fraction of 100‐250‐bp cfDNA fragments was higher at AR diagnosis compared with that of nonrejector patients (68.0% versus 57.9%, P = 0.02). STR amplification by QF‐PCR may be an alternative strategy for rapid ddcfDNA quantification, which is easily implementable in clinical laboratories. The results of this pilot study indicate that ddcfDNA increases very early, even 1‐2 weeks before the diagnosis of AR, and so it could be useful as a prognostic biomarker in improving patient risk stratification.

7 June 2011 in Transplant International
Verified
Journal Article
Open access
PDF file
DBDomingo Balderramo
Domingo Balderramo
JPJhon Prieto
Jhon Prieto
ACAndrés Cárdenas
Andrés Cárdenas
MNMiquel Navasa
Miquel Navasa
Early calcineurin inhibitor‐induced neurotoxicity (ECIIN) is considered when neurological symptoms occur within 4 weeks after liver transplantation (LT). Risk factors and clinical outcome of ECIIN remain largely unknown. We sought to estimate the incidence, risk factors, and outcome of ECIIN after LT. We retrospectively evaluated 158 patients that underwent LT in a 2‐year period and received immunosuppression with calcineurin inhibitors (CNI) and prednisone. ECIIN was considered when moderate/severe neurological events (after excluding other etiologies) occurred within 4 weeks after LT and improved after modification of CNI. Demographic and clinical variables were analyzed as risk factors. Twenty‐eight (18%) patients developed ECIIN and the remaining 130 patients were analyzed as controls. History of pre‐LT hepatic encephalopathy (OR 3.16, 95% CI 1.29–7.75, P = 0.012), post‐LT hyponatremia (OR 3.34, 95% CI 1.38–9.85, P = 0.028), and surgical time >7 h (OR 2.62, 95% CI 1.07–6.41, P = 0.035) were independent factors for ECIIN. Acute graft rejection and infections were more frequent in the ECIIN group. In addition, length of stay was longer in ECIIN patients. In conclusion, pre‐LT hepatic encephalopathy, surgical time >7 h, and post‐LT hyponatremia are risk factors for ECIIN. Clinical complications and a longer hospital stay are associated with ECIIN development.